Coherus Oncology

Company snapshot

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a promising pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Our strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination w

• 3 approved product(s) across US/EU regulatory metadata.
• 25 active pipeline program(s) linked via ClinicalTrials.gov.
• 73 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Coherus Oncology. Not investment advice.

• Peer + 0 momentum

  Universal Integrated

  TA overlap score 37.8

• Peer + 0 momentum

  Can Fite Biopharma

  TA overlap score 34

• Peer + 0 momentum

  Arcus Biosciences

  TA overlap score 30.6

• Peer + 0 momentum

  Chinese University of

  TA overlap score 28.4

• Peer + 0 momentum

  Aclaris Therapeutics

  TA overlap score 26.6

• Peer + 0 momentum

  Zentalis Pharmaceuticals

  TA overlap score 22.8

• Peer + 0 momentum

  IDEAYA Biosciences

  TA overlap score 22.8

• Peer + 0 momentum

  Tempest Therapeutics

  TA overlap score 20.6

• Peer + 0 momentum

  Werewolf Therapeutics

  TA overlap score 20.4

Recent activity

Latest pipeline, patent, and corporate events for Coherus Oncology.

1. Jun 8, 2026 Clinical update

   Toripalimab-tpzi — Phase 2

2. Jun 8, 2026 Clinical update

   Toripalimab — Phase 2

3. Jun 8, 2026 Clinical update

   Toripalimab — Approved

4. Jun 8, 2026 Clinical update

   Toripalimab — Phase 2

5. Jun 8, 2026 Clinical update

   Toripalimab — Phase 2

View all clinical trial activity →

• What is Coherus Oncology?

  Coherus Oncology is a pharma organization headquartered in Redwood City, USA. Primary therapeutic focus areas include Advanced Solid Tumor, Hepatocellular Carcinoma, Rheumatoid Arthritis, Plaque Psoriasis, Metastatic Solid Tumor. NovaPharmaNews links 25 clinical program(s), 3 dru

• Is Coherus Oncology publicly traded?

  Coherus Oncology appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Coherus Oncology develop or market?

  We link 11 drug profile(s) where Coherus Oncology is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/coherus-oncology#company-drugs.

• What are the latest developments for Coherus Oncology?

  In the last 12 months our linked public records show 25 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Coherus Oncology focus on?

  Coherus Oncology focuses on Advanced Solid Tumor, Hepatocellular Carcinoma, Rheumatoid Arthritis based on our analysis of their pipeline programs and drug development activities.